However, loss of MEG3 expression has been observed in multiple malignant cancers, including breast cancer, hepatocellular cancer and TSCC [131–133], and MEG3 silencing in cancer cells is mainly associated with its promoter hypermethylation [134]. Here, MEG3 is linked to hepatocellular carcinoma.